Example: tourism industry
EMPA-REG- CV Outcomes Trial Summary - RxFiles
RXFILES TRIAL SUMMARY .R . APR 2016 – WWW XFILES CA Page 1 of 3 EMPA-REG: CV Outcomes Trial Summary Empagliflozin: Cardiovascular (CV) Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus (T2DM) In patients with T2DM and at high risk of CV events, does empagliflozin reduce CV risk compared to placebo when added to standard care?
Tags:
Information
Domain:
Source:
Link to this page: